Download PDF

This activity is no longer available for credit, however its content is still (may still be) relevant for your educational needs.

Valid: March 30th, 2012 - March 30th, 2013

Target Audience

This activity was developed for pharmacists and other healthcare professionals practicing in a managed care environment.Learning Objectives

Learning Objectives

Upon completion of this activity, the participant will be able to:

  • Describe recent advances and emerging therapies in the treatment of patients with chemotherapy-induced nausea and vomiting (CINV)
  • Compare key recommendations from updated clinical practice guidelines for the management of CINV, including those established by ASCO, NCCN, MASCC, and ONS
  • Examine effective treatment strategies for preventing and improving outcomes in patients with CINV

Commercial Support Acknowledgment

This activity is supported by an educational grant from Eisai.

Registered Pharmacy Designation

Medical Learning Institute (MLI) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. Completion of this activity provides for 1.0 contact hour (0.1 CEU) of CE credit. The universal activity number for this activity is 0468-9999-12-005-H01-P.


Before the activity, all faculty and anyone who is in a position to have control over the content of this activity and their spouse/life partner will disclose the existence of any financial interest and/or relationship(s) they might have with any commercial interest producing healthcare goods/services to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speakers’ bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions. All identified conflicts of interest are thoroughly vetted by MLI for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

Planners’ and Managers’ Disclosures

Teresa Haile, RPh, MBA, has nothing to disclose.

Loretta M. Fala, medical write, has nothing to disclose.

Faculty Disclosures

Shawna Kraft, PharmD, BCOP, has nothing to disclose.

Joanna Schwartz, PharmD, BCOP, has nothing to disclose.

Rowena N. Schwartz, PharmD, BCOP, is a consultant for Amgen.

The associates of Medical Learning Institute, Inc., the accredited provider for this activity, and Center of Excellence Media, LLC, do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this CE activity for any amount during the past 12 months.


The information provided in this CE activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition. Recommendations for the use of particular therapeutic agents are based on the best available scientific evidence and current clinical guidelines. No bias toward or promotion for any agent discussed in this program should be inferred.

Related Items
Metastatic Breast Cancer: Advances in Treatment and Management
Joanna Schwartz, PharmD, BCOP, Georgia Litsas,MSN, ANP-BC, AOCNP
Supplements published on February 4, 2011
Considerations in Multiple Myeloma: Treatment-Naive Patients
Sagar Lonial, MD, Tiffany Andrews, MS, ANP, AOCNP, Rowena Schwartz, PharmD, BCOP
Supplements published on July 31, 2008
Last modified: March 21, 2014